TRDA
Entrada Therapeutics, Inc.NASDAQHealthcare$13.15+5.55%ClosedMarket Cap: $503.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.88
P/S
20.90
EV/EBITDA
-3.26
DCF Value
$9.91
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-54.4%
Operating Margin
-621.1%
Net Margin
-565.5%
ROE
-39.8%
ROA
-38.1%
ROIC
-44.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.3M | 31.8% | $-42.2M | $-39.2M | $-0.95 | — |
| FY 2025 | $25.4M | 83.9% | $-156.0M | $-143.8M | $-3.47 | — |
| Q3 2025 | $1.6M | -2276.8% | $-47.1M | $-44.1M | $-1.06 | — |
| Q2 2025 | $1.9M | 100.0% | $-46.8M | $-43.1M | $-1.04 | — |
| Q1 2025 | $20.6M | 100.0% | $-21.8M | $-17.3M | $-0.42 | — |
| Q4 2024 | $37.4M | 100.0% | $-5.9M | $1.1M | $0.03 | — |
| FY 2024 | $210.8M | 100.0% | $47.0M | $65.6M | $1.68 | — |
| Q3 2024 | $19.6M | 100.0% | $-21.7M | $-14.0M | $-0.35 | — |
| Q2 2024 | $94.7M | 100.0% | $53.4M | $55.0M | $1.55 | — |
| Q1 2024 | $59.1M | 100.0% | $21.1M | $23.5M | $0.68 | — |
| Q4 2023 | $41.8M | 100.0% | $4.9M | $-9.5M | $-0.29 | — |
| FY 2023 | $129.0M | 100.0% | $-3.2M | $-6.7M | $-0.20 | — |